BioSpace News Archive

Business

Pacira BioSciences Reports Third Quarter 2023 Financial Results

Pacira BioSciences, Inc. today reported financial results for the third quarter of 2023.

November 2, 2023
·
30 min read
Business

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

vTv Therapeutics Inc. announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately.

November 2, 2023
·
4 min read
BioMidwest

MIMEDX to Highlight Published Data at SAWC FallCompany Will Sponsor Lunch Symposium on November 3, 2023

MiMedx Group, Inc. announced it will sponsor an Innovation Theater lunch symposium at the Symposium on Advanced Wound Care Fall meeting taking place November 2-5 in Las Vegas, NV.

November 2, 2023
·
3 min read
Drug Development

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. announced the successful outcome of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration, supporting the advancement of oral APX3330 for the treatment of diabetic retinopathy into Phase 3 studies based on the recently completed Phase 2 ZETA-1 trial.

November 2, 2023
·
8 min read
Immutep to Participate in November 2023 Investor Events

Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announces its management will participate in the following upcoming investor events in November.

November 2, 2023
·
1 min read
Pharm Country

BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care

BioSig Technologies, Inc. announced that Mayo Clinic-Phoenix has upgraded to the Platform’s subscription model to gain immediate access to the Company’s latest technological advancements in cardiac arrhythmia identification.

November 2, 2023
·
7 min read
Policy

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

I-Mab and HI-Bio announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for felzartamab, an investigational CD38 antibody, for the treatment of primary membranous nephropathy.

November 2, 2023
·
8 min read
Biotech Beach

AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)

Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA ® (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment − uncontrolled gout − both with and without chronic kidney disease (CKD).

November 2, 2023
·
14 min read
Business

Curis Provides Third Quarter 2023 Business Update

Curis, Inc. today reported its business update and financial results for the quarter ended September 30, 2023.

November 2, 2023
·
11 min read
Business

ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors

ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis and other debilitating brain diseases, announced the initial closing of a $15 million Series A financing.

November 2, 2023
·
3 min read